Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBT Margin (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed EBT Margin for 9 consecutive years, with 4322.37% as the latest value for Q4 2025.

  • Quarterly EBT Margin changed N/A to 4322.37% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11627.88% through Dec 2025, changed N/A year-over-year, with the annual reading at 11627.88% for FY2025, N/A changed from the prior year.
  • EBT Margin hit 4322.37% in Q4 2025 for Seres Therapeutics, up from 6227.64% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 53.86% in Q3 2021 to a low of 13694.25% in Q1 2023.
  • Historically, EBT Margin has averaged 3647.67% across 4 years, with a median of 1327.07% in 2021.
  • Biggest YoY gain for EBT Margin was 533660bps in 2023; the steepest drop was -1181164bps in 2023.
  • Year by year, EBT Margin stood at 688.06% in 2021, then surged by 67bps to 225.33% in 2022, then surged by 112bps to 27.76% in 2023, then tumbled by -15669bps to 4322.37% in 2025.
  • Business Quant data shows EBT Margin for MCRB at 4322.37% in Q4 2025, 6227.64% in Q3 2025, and 27.76% in Q4 2023.